Patents Assigned to Cypralis Limited
  • Macrocyclic inhibitors of flaviviridae viruses
    Patent number: 10472392
    Abstract: Provided are compounds of Formula I: and pharmaceutically acceptable salts and esters thereof. The compounds, compositions, and methods provided are useful for the treatment of virus infections, particularly hepatitis C infections.
    Type: Grant
    Filed: February 2, 2017
    Date of Patent: November 12, 2019
    Assignees: Gilead Sciences, Inc., Cypralis Limited
    Inventors: Caroline Aciro, Jean Yves Chiva, David Kenneth Dean, Adrian John Highton, Petr Jansa, Andrew John Keats, Linos Lazarides, Richard Mackman, Karine G. Poullennec, Adam James Schrier, Dustin Scott Siegel, Victoria Alexandra Steadman, Greg Watt
  • Macrocyclic inhibitors of flaviviridae viruses
    Patent number: 10246486
    Abstract: Provided are compounds of Formula I: and pharmaceutically acceptable salts and esters thereof. The compounds, compositions, and methods provided are useful for the treatment of virus infections, particularly hepatitis C infections.
    Type: Grant
    Filed: March 21, 2017
    Date of Patent: April 2, 2019
    Assignees: Gilead Sciences, Inc., Cypralis Limited
    Inventors: Caroline Aciro, David Kenneth Dean, Neil Andrew Dunbar, Adrian John Highton, Petr Jansa, Kapil Kumar Karki, Andrew John Keats, Linos Lazarides, Richard Mackman, Simon Neil Pettit, Karine G. Poullennec, Adam James Schrier, Dustin Scott Siegel, Victoria Alexandra Steadman
  • Cyclic depsipeptide compounds and their uses
    Patent number: 9895412
    Abstract: The present invention relates to novel cycloundecadepsipeptide compounds and their analogues which bind and inhibit cyclophilins, have reduced immunosuppressive activity and improved physicochemical properties including water solubility. The present invention further relates to pharmaceutical compositions containing said depsipeptide compounds and their analogues for use in the treatment or prevention of diseases and pathologies which may be ameliorated by the inhibition of cyclophilin activity.
    Type: Grant
    Filed: June 20, 2016
    Date of Patent: February 20, 2018
    Assignee: Cypralis Limited
    Inventors: Hans Georg Fliri, Rhonan Lee Ford, Antonio Kuok Keong Vong
  • Macrocyclic inhibitors of flaviviridae viruses
    Patent number: 9873716
    Abstract: Provided are compounds of Formula I: and pharmaceutically acceptable salts and esters thereof. The compounds, compositions, and methods provided are useful for the treatment of virus infections, particularly hepatitis C infections.
    Type: Grant
    Filed: June 16, 2015
    Date of Patent: January 23, 2018
    Assignees: Gilead Sciences, Inc., Cypralis Limited
    Inventors: Caroline Aciro, David Kenneth Dean, Neil Andrew Dunbar, Adrian John Highton, Petr Jansa, Kapil Kumar Karki, Andrew J. Keats, Linos Lazarides, Richard L. Mackman, Simon N. Pettit, Karine G. Poullennec, Adam James Schrier, Dustin Siegel, Victoria Alexandra Steadman
  • Cyclic depsipeptide compounds and their uses
    Patent number: 9382295
    Abstract: The present invention relates to novel cycloundecadepsipeptide compounds and their analoges which bind and inhibit cyclophilins, have reduced immunosuppressive activity and improved physicochemical properties including water solubility. The present invention further relates to pharmaceutical compositions containing said depsipeptide compounds and their analoges for use in the treatment or prevention of diseases and pathologies which may be ameliorated by the inhibition of cyclophilin activity.
    Type: Grant
    Filed: October 2, 2013
    Date of Patent: July 5, 2016
    Assignee: Cypralis Limited
    Inventors: Hans Georg Fliri, Rhonan Lee Ford, Antonio Kuok Keong Vong
  • Macrocyclic inhibitors of flaviviridae viruses
    Patent number: RE47334
    Abstract: Provided are compounds of Formula I: and pharmaceutically acceptable salts and esters thereof. The compounds, compositions, and methods provided are useful for the treatment of virus infections, particularly hepatitis C infections.
    Type: Grant
    Filed: September 25, 2017
    Date of Patent: April 2, 2019
    Assignees: Gilead Sciences, Inc., Cypralis Limited
    Inventors: Caroline Aciro, Victoria Alexandra Steadman, Simon Neil Pettit, Karine G. Poullennec, Linos Lazarides, David Kenneth Dean, Neil Andrew Dunbar, Adrian John Highton, Andrew John Keats, Dustin Scott Siegel, Kapil Kumar Karki, Adam James Schrier, Petr Jansa, Richard Mackman, Jean Yves Chiva